Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma
Yıl: 2022 Cilt: 54 Sayı: 1 Sayfa Aralığı: 77 - 79 Metin Dili: İngilizce DOI: 10.5152/eurasianjmed.2022.20300 İndeks Tarihi: 24-06-2022
Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma
Öz: Everolimus-associated cytomegalovirus colitis is very rare in cancer patients. We present a case of cytomegalovirus colitis that occurred on using everolimus in a 64-year-old male with metastatic renal cell carcinoma
who received pazopanib, nivolumab, and everolimus treatments, respectively. Although an increasing number
of nivolumab-related cytomegalovirus colitis cases are reported recently, its mechanism of development is
still unknown. Our study highlights that clinicians should remember cytomegalovirus reactivation in the presence of diarrhea or colitis in patients receiving everolimus and/or nivolumab. Further studies are needed
to elucidate the relationship between immune checkpoint inhibitors and cytomegalovirus reactivation, and
these will also be a guide to prevent other possible viral infections.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Editöre Mektup Erişim Türü: Erişime Açık
- 1. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-456. [CrossRef]
- 2. Tan L, Sato N, Shiraki A, et al. Everolimus delayed and suppressed cytomegalovirus DNA synthesis, spread of the infection, and alleviated cytomegalovirus infection. Antiviral Res. 2019;162:30-38. [CrossRef]
- 3. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706-720. [CrossRef]
- 4. Havenith SHC, Yong SL, Van Donselaar-Van Der Pant KAMI, van Lier RA, ten Berge IJ, Bemelman FJ. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine-or mycophenolate-treated patients. Transplantation. 2013;95(1):184-191. [CrossRef]
- 5. Yang JR, Shao YC. Everolimus-associated cytomegalovirus colitis in a patient with metastasized breast cancer: a case report. Breast Cancer. 2020;27(4):776-779. [CrossRef]
- 6. Prieux-Klotz C, Dior M, Damotte D, et al. Immune checkpoint inhibitor-induced colitis: diagnosis and management. Target Oncol. 2017;12(3):301-308. [CrossRef]
- 7. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375-384. [CrossRef]
- 8. Assarzadegan N, Montgomery E, Anders RA. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Arch. 2018;472(1):125-133. [CrossRef]
- 9. Lankes K, Hundorfean G, Harrer T, et al. AntiTNF-refractory colitis after checkpoint inhibitor therapy: possible role of CMV-mediated immunopathogenesis. Oncoimmunology. 2016;5(6):e1128611. [CrossRef]
- 10. Franklin C, Rooms I, Fiedler M, et al. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. Eur J Cancer. 2017;86:248-256. [CrossRef]
- 11. Cañete F, Mañosa M, Lobatón T, et al. Nivolumabinduced immune-mediated colitis: an ulcerative colitis look-alike—report of new cases and review of the literature. Int J Colorectal Dis. 2019;34(5):861-865. [CrossRef]
- 12. Van Turenhout ST, Berghuis M, Snaebjornsson P, et al. Cytomegalovirus in steroid-refractory immune checkpoint inhibition–related colitis. J Thorac Oncol. 2020;15(1):e15-e20. [CrossRef]
- 13. Medicines and Healthcare products Regulatory Agency (MHRA). Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation. Drug Saf Update. 2019;13(3).
| APA | Ismayilov R, AKTEPE O, Sardarova K, Leblebici C, erman m (2022). Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma. , 77 - 79. 10.5152/eurasianjmed.2022.20300 |
| Chicago | Ismayilov Rashad,AKTEPE Oktay Halit,Sardarova Konul,Leblebici Can Berk,erman mustafa Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma. (2022): 77 - 79. 10.5152/eurasianjmed.2022.20300 |
| MLA | Ismayilov Rashad,AKTEPE Oktay Halit,Sardarova Konul,Leblebici Can Berk,erman mustafa Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma. , 2022, ss.77 - 79. 10.5152/eurasianjmed.2022.20300 |
| AMA | Ismayilov R,AKTEPE O,Sardarova K,Leblebici C,erman m Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma. . 2022; 77 - 79. 10.5152/eurasianjmed.2022.20300 |
| Vancouver | Ismayilov R,AKTEPE O,Sardarova K,Leblebici C,erman m Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma. . 2022; 77 - 79. 10.5152/eurasianjmed.2022.20300 |
| IEEE | Ismayilov R,AKTEPE O,Sardarova K,Leblebici C,erman m "Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma." , ss.77 - 79, 2022. 10.5152/eurasianjmed.2022.20300 |
| ISNAD | Ismayilov, Rashad vd. "Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma". (2022), 77-79. https://doi.org/10.5152/eurasianjmed.2022.20300 |
| APA | Ismayilov R, AKTEPE O, Sardarova K, Leblebici C, erman m (2022). Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma. Eurasian Journal of Medicine, 54(1), 77 - 79. 10.5152/eurasianjmed.2022.20300 |
| Chicago | Ismayilov Rashad,AKTEPE Oktay Halit,Sardarova Konul,Leblebici Can Berk,erman mustafa Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma. Eurasian Journal of Medicine 54, no.1 (2022): 77 - 79. 10.5152/eurasianjmed.2022.20300 |
| MLA | Ismayilov Rashad,AKTEPE Oktay Halit,Sardarova Konul,Leblebici Can Berk,erman mustafa Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma. Eurasian Journal of Medicine, vol.54, no.1, 2022, ss.77 - 79. 10.5152/eurasianjmed.2022.20300 |
| AMA | Ismayilov R,AKTEPE O,Sardarova K,Leblebici C,erman m Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma. Eurasian Journal of Medicine. 2022; 54(1): 77 - 79. 10.5152/eurasianjmed.2022.20300 |
| Vancouver | Ismayilov R,AKTEPE O,Sardarova K,Leblebici C,erman m Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma. Eurasian Journal of Medicine. 2022; 54(1): 77 - 79. 10.5152/eurasianjmed.2022.20300 |
| IEEE | Ismayilov R,AKTEPE O,Sardarova K,Leblebici C,erman m "Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma." Eurasian Journal of Medicine, 54, ss.77 - 79, 2022. 10.5152/eurasianjmed.2022.20300 |
| ISNAD | Ismayilov, Rashad vd. "Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma". Eurasian Journal of Medicine 54/1 (2022), 77-79. https://doi.org/10.5152/eurasianjmed.2022.20300 |
